BIO
Bio-Rad Laboratories, Inc.NYSEHealthcare$279.99+0.59%ClosedMarket Cap: $7.56B
As of 2026-04-06
Valuation
P/E (TTM)
9.94
PEG
0.07
P/B
1.01
P/S
2.93
EV/EBITDA
10.12
DCF Value
$-208.97
FCF Yield
5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
51.9%
Operating Margin
8.9%
Net Margin
29.4%
ROE
10.9%
ROA
7.7%
ROIC
1.7%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $693.2M | 49.8% | $61.9M | $720.0M | $26.65 | — |
| FY 2025 | $2.58B | 52.0% | $270.5M | $759.9M | $27.87 | — |
| Q3 2025 | $653.0M | 52.6% | $66.4M | $-341.9M | $-12.70 | — |
| Q2 2025 | $651.6M | 53.0% | $77.1M | $317.8M | $11.67 | — |
| Q1 2025 | $585.4M | 52.3% | $23.7M | $64.0M | $2.29 | — |
| Q4 2024 | $667.5M | 51.2% | $58.3M | $-715.8M | $-25.57 | — |
| FY 2024 | $2.57B | 53.7% | $269.0M | $-1.84B | $-65.36 | — |
| Q3 2024 | $649.7M | 54.8% | $64.5M | $653.2M | $23.34 | — |
| Q2 2024 | $638.5M | 55.6% | $101.5M | $-2.17B | $-76.26 | — |
| Q1 2024 | $610.8M | 53.4% | $52.0M | $383.9M | $13.45 | — |
| Q4 2023 | $681.2M | 53.7% | $97.8M | $349.7M | $12.14 | — |
| FY 2023 | $2.67B | 53.4% | $337.8M | $-637.3M | $-21.82 | — |